Drug-Target Residence Time-A Case for G Protein-Coupled Receptors

Medicinal Research Reviews

Volumn 34, Issue 4, 2014, Pages 856-892

  Guo, Dong ^a   Hillger, Julia M ^a   Ijzerman, Adriaan P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Dissociation rate; Drug discovery; GPCR; Residence time

Indexed keywords

2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; ACLIDINIUM BROMIDE; APREPITANT; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; JNJ 37822681; MEN 1149; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; PF 3635659; QUETIAPINE; RADIOLIGAND; TACHYKININ RECEPTOR; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VESTIPITANT; LIGAND;

ARTICLE; BINDING KINETICS; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGET RESIDENCE TIME; DRUG TARGETING; IC 50; LIGAND BINDING; MATHEMATICAL ANALYSIS; PHARMACODYNAMICS; STRUCTURE ACTIVITY RELATION; CHEMISTRY; HUMAN; KINETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TIME;

HUMANS; KINETICS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84901827515     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21307     Document Type: Article

References (182)

1. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5(9):730-739.
2. Swinney DC. Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Discov 2006;3(8):569-574.
3. Swinney DC. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: Mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 2006;6(5):461-478.
4. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10(7):507-519.
5. Swinney DC. Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 2004;3(9):801-808.
6. Copeland RA. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. New York: John Wiley & Sons; 2005. p 153.
7. Copeland RA. Conformational adaptation in drug-target interactions and residence time. Future Med Chem 2011;3(12):1491-1501.
8. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010;161(3):488-508.
9. 1 receptor antagonism: The need for different antagonist binding states of the receptor. Trends Pharmacol Sci 2001;22(7):343-344.
10. Vauquelin G, Morsing P, Fierens FL, De Backer JP, Vanderheyden PM. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol 2001;61(3):277-284.
11. Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006;27(7):356-359.
12. Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Dev 2009;12(4):488-496.
13. Zhang R, Monsma F. Binding kinetics and mechanism of action: Toward the discovery and development of better and best in class drugs. Expert Opin Drug Discov 2010;5(11):1023-1029.
14. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47(20):5481-5492.
15. Dahl G, Akerud T. Pharmacokinetics and the drug-target residence time concept. Drug Discov Today 2013;18(15-16):697-707.
16. Nunez S, Venhorst J, Kruse CG. Target-drug interactions: First principles and their application to drug discovery. Drug Discov Today 2012;17(1-2):10-22.
17. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Dev 2009;12(1):31-39.
18. Vilums M, Zweemer AJ, Yu Z, de Vries H, Hillger JM, Wapenaar H, Bollen IA, Barmare F, Gross R, Clemens J, Krenitsky P, Brussee J, Stamos D, Saunders J, Heitman LH, IJzerman AP. Structure-kinetic relationships-An overlooked parameter in hit-to-lead optimization: A case of cyclopentylamines as chemokine receptor 2 antagonists. J Med Chem 2013;56(19):7706-7714.
19. Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, Eiermann G, Tsou NN, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, MacIntyre DE. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1, 2, 4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998;41(23):4607-4614.
20. Gavalda A, Miralpeix M, Ramos I, Otal R, Carreno C, Vinals M, Domenech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331(2):740-751.
21. Keppler A, Gendreizig S, Gronemeyer T, Pick H, Vogel H, Johnsson K. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 2003;21(1):86-89.
22. 2 Receptor Using a Platform for GPCR Applications, Vol. 2013. Bedford: American Laboratory; 2011.
23. Leysen JE, Gommeren W. The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method. J Recept Res 1984;4(7):817-845.
24. 1 receptors. J Recept Signal Transduct Res 2009;29(2):84-93.
25. Packeu A, Wennerberg M, Balendran A, Vauquelin G. Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach. Br J Pharmacol 2010;161(6):1311-1328.
26. 2 receptor. Bioorg Med Chem 2011;19(7):2231-2241.
27. 3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci USA 1985;82(3):925-929.
28. Contreras ML, Wolfe BB, Molinoff PB. Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther 1986;239(1):136-143.
29. 3 receptor. Br J Pharmacol 2006;148(7):927-937.
30. Heise CE, Sullivan SK, Crowe PD. Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen 2007;12(2):235-239.
31. 3 receptors. Br J Pharmacol 2011;164(6):1627-1641.
32. 2A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 2012;166(6):1846-1859.
33. Guo D, van Dorp EJ, Mulder-Krieger T, van Veldhoven JP, Brussee J, IJzerman AP, Heitman LH. Dual-point competition association assay: A fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen 2013;18(3):309-320.
34. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 1984;25(1):1-9.
35. 2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 2012;385(4):337-372.
36. Gaddum JH, Hameed KA, Hathway DE, Stephens FF. Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol Cogn Med Sci 1955;40(1):49-74.
37. Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006;319(2):710-723.
38. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol 1967;191(1):59-90.
39. Paton WDM, Rang HP. A kinetic approach to the mechanism of drug action. In: Harper NJ, Simmonds AB, Eds. Advances in Drug Research. London & New York: Academic Press; 1998. p 57-80.
40. Rang HP. The kinetics of action of acetylcholine antagonists in smooth muscle. Proc R Soc Lond B Biol Sci 1966;164(996):488-510.
41. 1 receptor antagonists: The role of tight antagonist binding. Eur J Pharmacol 1999;372(2):199-206.
42. 1-receptor antagonists be explained? Cell Biochem Biophys 2001;35(1):89-102.
43. 1-receptor antagonists. J Renin-Angio-Aldo Syst 2001;2(1 Suppl):S24-S31.
44. Vauquelin G, Van Liefde I, Birzbier BB, Vanderheyden PM. New insights in insurmountable antagonism. Fundam Clin Pharmacol 2002;16(4):263-272.
45. Vauquelin G, Van Liefde I, Vanderheyden P. Models and methods for studying insurmountable antagonism. Trends Pharmacol Sci 2002;23(11):514-518.
46. Vauquelin G, Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochem Int 2007;51(5):254-260.
47. Shiau AK, Massari ME, Ozbal CC. Back to basics: Label-free technologies for small molecule screening. Comb Chem High T Scr 2008;11(3):231-237.
48. Rich RL, Myszka DG. Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem 2007;361(1):1-6.
49. Gronewold TMA, Baumgartner A, Hierer J, Sierra S, Blind M, Schafer F, Blumer J, Tillmann T, Kiwitz A, Kaiser R, Zabe-Kuhn M, Quandt E, Famulok M. Kinetic binding analysis of aptamers targeting HIV-1 proteins by a combination of a microbalance array and mass spectrometry (MAMS). J Proteome Res 2009;8(7):3568-3577.
50. Gronewold TMA. Surface acoustic wave sensors in the bioanalytical field: Recent trends and challenges. Anal. Chim. Acta 2007;603(2):119-128.
51. Rich RL, Myszka DG. Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'. J Mol Recogn 2010;23(1):1-64.
52. 2A receptor. J Med Chem 2011;54(13):4312-4323.
53. Robertson N, Jazayeri A, Errey J, Baig A, Hurrell E, Zhukov A, Langmead CJ, Weir M, Marshall FH. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 2011;60(1):36-44.
54. Congreve M, Andrews SP, Dore AS, Hollenstein K, Hurrell E, Langmead CJ, Mason JS, Ng IW, Tehan B, Zhukov A, Weir M, Marshall FH. Discovery of 1, 2, 4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem 2012;55(5):1898-1903.
55. Navratilova I, Dioszegi M, Myszka DG. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Anal Biochem 2006;355(1):132-139.
56. Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schioth HB. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 2006;88(3):263-273.
57. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3(9):639-650.
58. De Amici M, Dallanoce C, Holzgrabe U, Trankle C, Mohr K. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Med Res Rev 2010;30(3):463-549.
59. Overington JP, Al-Lazikani B, Hopkins AL. Opinion-How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-996.
60. Russ AP, Lampel S. The druggable genome: An update. Drug Discov Today 2005;10(23-24):1607-1610.
61. Chen L, Jin L, Zhou N. An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov 2012;7(9):791-806.
62. 12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res 2008;122(4):533-540.
63. Foldes FF. Pain control with intrathecally and peridurally administered opioids and other drugs. Anaesthesiol Reanim 1991;16(5):287-298.
64. Laduron PM, Janssen PFM. Axoplasmic-transport and possible recycling of opiate receptors labeled with H-3-labeled lofentanil. Life Sci 1982;31(5):457-462.
65. Savoia G, Loreto M, Gravino E. Sufentanil: an overview of its use for acute pain management. Minerva Anestesiol 2001;67(9 Suppl 1):206-216.
66. Patel S, Spencer C. Remifentanil. Drugs 1996;52(3):417-427.
67. Pan AC, Borhani DW, Dror RO, Shaw DE. Molecular determinants of drug-receptor binding kinetics. Drug Discov Today 2013;18(13-14):667-673.
68. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-715.
69. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008;83(2):227-230.
70. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50(2):279-290.
71. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237(4814):527-532.
72. Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989;12(4):148-151.
73. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996;10(1):69-99.
74. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(Suppl 12A):24S-32S.
75. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.
76. Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005;11(2):121-128.
77. Disse B, Speck GA, Rominger KL, Witek TJ, Jr., Hammer R. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64(6-7):457-464.
78. Disse B, Reichl R, Speck G, Traunecker W, Rominger KL, Hammer R. Ba 679 Br, a novel long-acting anticholinergic bronchodilator. Life Sci 1993;52(5-6):537-544.
79. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45(5):899-907.
80. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: Comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009;330(2):660-668.
81. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Renard E, Trifilieff A, Charlton SJ. The influence of receptor kinetics on the onset and duration of action, and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012;343(2):520-528.
82. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu YM, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: The GLOW1 trial. Resp Res 2011;12:156.
83. 3 receptor. J Med Chem 2013;56(21):8746-8756.
84. 3 muscarinic acetylcholine receptor. Nature 2012;482(7386):552-556.
85. Smith DA, Jones BC, Walker DK. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996;16(3):243-266.
86. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-1554.
87. van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19(4):639-644.
88. Traynor K. Aclidinium bromide oral inhalation powder approved for COPD. Am J Health Syst Pharm 2012;69(17):1446.
89. Prat M, Fernandez D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleon JM, Gavalda A, Miralpeix M, Ramos I, Domenech T, Vilella D, Anton F, Huerta JM, Espinosa S, Lopez M, Sentellas S, Gonzalez M, Alberti J, Segarra V, Cardenas A, Beleta J, Ryder H. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: Identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem 2009;52(16):5076-5092.
90. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130(6):1695-1703.
91. Suppli Ulrik C. Aclidinium bromide: Clinical benefit in patients with moderate to severe COPD. Open Respir Med J 2012;6:150-154.
92. Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012;25(3):248-253.
93. Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2012;6(6):345-361.
94. Gupta V, Singh D. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2012;6(6):581-588.
95. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012;40(4):830-836.
96. 3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54(19):6888-6904.
97. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999;127(2):413-420.
98. 3 receptor. Mol Pharmacol 2009;76(3):543-551.
99. 2A-autoreceptor: Role of binding duration. Naunyn Schmiedebergs Arch Pharmacol 2008;378(1):17-26.
100. Pantaleo N, Chadwick W, Park SS, Wang L, Zhou Y, Martin B, Maudsley S. The mammalian tachykinin ligand-receptor system: An emerging target for central neurological disorders. CNS Neurol Disord Drug Targets 2010;9(5):627-635.
101. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: A growing family. Life Sci 2004;74(12):1445-1463.
102. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, Candenas ML. Tachykinins and tachykinin receptors: Structure and activity relationships. Curr Med Chem 2004;11(15):2045-2081.
103. 3 receptor antagonists for the treatment of schizophrenia and other CNS indications. Curr Opin Drug Discov Dev 2010;13(4):379-388.
104. Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol 2001;41:877-906.
105. Albert JS. Neurokinin antagonists and their potential role in treating depression and other stress disorders. Exp Opin Investig Drugs 2004;14(10):1421-1433.
106. Lecci A, Maggi CA. Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Exp Opin Ther Targets 2003;7(3):343-362.
107. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Exp Opin Investig Drugs 2009;18(12):1843-1864.
108. Lindstrom E, von Mentzer B, Pahlman I, Ahlstedt I, Uvebrant A, Kristensson E, Martinsson R, Noven A, de Verdier J, Vauquelin G. Neurokinin 1 receptor antagonists: Correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 2007;322(3):1286-1293.
109. 1 antagonists. J Pharmacol Exp Ther 2002;301(2):536-542.
110. 3 receptors. Br J Pharmacol 2011;162(4):929-946.
111. 1 receptor antagonist. Eur J Pharmacol 1997;325(2-3):253-261.
112. Cascieri MA, Ber E, Fong TM, Sadowski S, Bansal A, Swain C, Seward E, Frances B, Burns D, Strader CD. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Mol Pharmacol 1992;42(3):458-463.
113. 1 receptor activation in gerbils. Eur J Pharmacol 1994;253(3):245-252.
114. 1 antagonists. Bioorg Med Chem Lett 2007;17(19):5310-5315.
115. 1 receptor. Bioorg Med Chem Lett 2010;20(19):5925-5932.
116. 1 antagonists. Bioorg Med Chem 2008;16(5):2156-2170.
117. 1 antagonists. Bioorg Med Chem Lett 2010;20(6):2007-2012.
118. 1 receptor. Bioorg Med Chem Lett 2010;20(19):5925-5932.
119. 1 receptor antagonist. J Med Chem 2009;52(10):3238-3247.
120. 1) receptor antagonist clinical candidate. J Med Chem 2011;54(4):1071-1079.
121. 1 receptor antagonist. Eur J Pharmacol 1998;341(2-3):201-209.
122. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as reserpine antagonists. Nature 1957;180(4596):1200-1200.
123. Le Crom S, Kapsimali M, Barome PO, Vernier P. Dopamine receptors for every species: Gene duplications and functional diversification in Craniates. J Struct Funct Genomics 2003;3(1-4):161-176.
124. Carlsson A, Civelli O, Kebabian J, Langer S, Scatton B, Schwartz JC, Sedvall G, Seeman P, Sokoloff P, Spano P, Van Tol H. Dopamine receptors. Last modified on May 27, 2013. Accessed on August 29, 2013. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=20.
125. Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 2006;111(3):715-728.
126. 2 receptor binding potential in social phobia. Am J Psychiatry 2000;157(3):457-459.
127. Kienast T, Heinz A. Dopamine and the diseased brain. CNS Neurol Disord Drug Targets 2006;5(1):109-131.
128. Fuxe K, Manger P, Genedani S, Agnati L. In: Riederer P, Reichmann H, Youdim MBH, Gerlach M, Eds. Parkinson's Diseases and Related Disorders. Vienna: Springer; 2006. p 71-83.
129. 3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B 2003;117B(1):57-60.
130. Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006;67:13-20.
131. 1 dopamine receptor: A putative neurochemical and behavioral link to cocaine action. J Cell Physiol 2002;191(1):17-27.
132. 2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 2005;102(9):3513-3518.
133. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10(1):79-104.
134. 2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 2000;25(2):161-166.
135. 2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 2012;342(1):91-105.
136. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-288.
137. Bartholi G, Haefely W, Jalfre M, Keller HH, Pletsche A. Effects of clozapine on cerebral catecholaminergic neuron systems. Br J Pharmacol 1972;46(4):736-740.
138. 2 dopamine receptor occupancy in low EPS-incidence drugs: PET evidence. Biol Psychiatry 2000;47(8):112s-112s.
139. 2 receptor is linked to reduced prolactin release. Int J Neuropsychopharmacol 2012;15(5):645-656.
140. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360-369.
141. 2 receptor antagonist, in healthy subjects using positron emission tomography: Single dose versus steady state and dose selection. Psychopharmacology (Berl) 2012;224(4):549-557.
142. 2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. Eur Neuropsychopharmacol 2012;22(10):721-733.
143. Miller DC, Lunn G, Jones P, Sabnis Y, Davies NL, Driscoll P. Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target. MedChemComm 2012;3(4):449-452.
144. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213(4514):1394-1397.
145. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: Yet more partners discovered. Trends Pharmacol Sci 2002;23(2):71-77.
146. Bale TL, Vale WW. CRF and CRF receptors: Role in stress responsivity and other behaviors. Annu Rev Pharmacol 2004;44:525-557.
147. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD, Winston EN, Chen YL, Heym J. CP-154, 526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996;93(19):10477-10482.
148. Grigoriadis DE. The corticotropin-releasing factor receptor: A novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005;9(4):651-684.
149. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23(5):477-501.
150. Chen C. Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. Curr Med Chem 2006;13(11):1261-1282.
151. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 2012;341(2):518-531.
152. Miller DC, Klute W, Brown AD. Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles. Bioorg Med Chem Lett 2011;21(20):6108-6111.
153. 1 receptors in vitro and in vivo. Br J Pharmacol 2011;164(3):992-1007.
154. Gilligan PJ, Robertson DW, Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents. J Med Chem 2000;43(9):1641-1660.
155. 1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 2002;1(5):467-493.
156. Hollenstein K, Kean J, Bortolato A, Cheng RKY, Dore AS, Jazayeri A, Cooke RM, Weir M, Marshall FH. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013;499(7459):438-443.
157. Arvanitis AG, Gilligan PJ, Chorvat RJ, Cheeseman RS, Christos TE, Bakthavatchalam R, Beck JP, Cocuzza AJ, Hobbs FW, Wilde RG, Arnold C, Chidester D, Curry M, He L, Hollis A, Klaczkiewicz J, Krenitsky PJ, Rescinito JP, Scholfield E, Culp S, De Souza EB, Fitzgerald L, Grigoriadis D, Tam SW, Wong YN, Huang S, Shen HL. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J Med Chem 1999;42(5):805-818.
158. Hodge CN, Aldrich PE, Wasserman ZR, Fernandez CH, Nemeth GA, Arvanitis A, Cheeseman RS, Chorvat RJ, Ciganek E, Christos TE, Gilligan PJ, Krenitsky P, Scholfield E, Strucely P. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies. J Med Chem 1999;42(5):819-832.
159. Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2011;2(5):349-355.
160. 2 receptor: A receptor-transducer coupling model to explain insurmountable antagonist effects. Drug Dev Res 1986;8(1-4):173-178.
161. Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M. Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 2006;70(4):1264-1270.
162. 1-adrenoceptor antagonist when compared to other beta-blockers. Biol Pharm Bull 1995;18(8):1066-1071.
163. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, Pieper M, Sieger P, Gantner F. Functional and biochemical rationales for the 24-hour long duration of action of olodaterol. J Pharmacol Exp Ther 2011;337(3):600-609.
164. 1 antagonists, and opiates. Drug Dev Res 1986;8(1-4):119-131.
165. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005;67(4):1268-1282.
166. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007;322(2):477-485.
167. 2 receptor antagonist. Bioorg Med Chem Lett 2011;21(3):1036-1040.
168. Sullivan SK, Hoare SRJ, Fleck BA, Zhu YF, Heise CE, Struthers RS, Crowe PD. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism. Biochem Pharmacol 2006;72(7):838-849.
169. 1 receptor. Eur J Pharmacol 2002;449(3):229-237.
170. 4 receptor antagonists; fragment optimization and analysis of binding kinetics. Bioorg Med Chem Lett 2012;22(1):461-467.
171. 2 receptor. J Pharmacol Exp Ther 2009;329(2):486-495.
172. Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, Wettstein JG, Bissantz C. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures. J Med Chem 2009;52(22):7103-7112.
173. Mould R, Brown J, Marshall FH, Langmead CJ. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol 2014;171(2):351-363.
174. 3H]apafant, a selective and competitive platelet-activating factor antagonist: Evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Mol Pharmacol 1993;43(2):302-312.
175. Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. Br J Pharmacol 2010;161(1):207-228.
176. 5-selective radioligand. Eur J Pharmacol 2008;601(1-3):1-7.
177. 1R inverse agonist, in obese and overweight patients: A high-dose study. Int J Obes (Lond) 2010;34(5):919-935.
178. 1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab 2010;12(6):517-531.
179. http://clinicaltrials.gov/
180. Meltzer HY. Multireceptor atypical antipsychotic drugs. In: Ellenbroek BA, Cools AR, Eds. Atypical Antipsychotics. Basel: Birkhauser Verlag; 2000. p 191-213.
181. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358(9295):1793-1803.
182. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Monteillet-Agius G, Stewart PL, Evans CJ, von Zastrow M. mu-Opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998;53(3):377-384.